We analysed 42 dierentiated thyroid tumors including 15 follicular adenomas (FA), 13 papillary thyroid cancers (PTC) and 14 follicular thyroid carcinomas (FTC) with 13 microsatellite markers speci®c for the long arm of human chromosome 7 within 7q31; this region is deleted frequently in several other tumor types. Overall, 20 of the 42 samples analysed (48%) displayed LOH with one or more of the markers tested. LOH was detected most frequently (78%) in FTC, the most malignant of the thyroid tumors. A smallest common deleted region (SCDR) was de®ned in this tumor typē anked by markers D7S480 and D7S490. This SCDR is distinct from D7S522, the most commonly deleted locus in many other tumors, which was deleted in only one FTC. D7S522 did show LOH in two of six informative PTCs. None of the PTC and only two of the FAs showed LOH in the FTC SCDR. Since FA is considered a premalignant stage of FTC, our results suggest that inactivation of a putative tumor suppressor at 7q31.2 may be acquired during adenoma to carcinoma progression. The absence of LOH at this locus amongst PTC suggests that inactivation of this tumor suppressor is speci®c for FTC. In conclusion, LOH at 7q31 is a frequent event in dierentiated thyroid cancer, and we have de®ned a 2 cM SCDR speci®c for FTC.
Introduction
Loss of heterozygosity (LOH) in a chromosomal region is generally the ®rst indication that a speci®c region may harbor a putative tumor suppressor gene (TSG) (Edelson et al., 1996; Knudson, 1993; Lin et al., 1996; Weinberg, 1991; Zenklusen et al., 1994a) . Recent studies have shown frequent LOH of microsatellite markers on the long arm of chromosome 7, speci®cally at band q31 in several types of tumor including breast (Devilee et al., 1997; Lin et al., 1996; Zenklusen et al., 1994a) , ovarian (Koike et al., 1997; Zenklusen et al., 1995a) , pancreatic (Achille et al., 1996) , prostatic (Oakahashi et al., 1995; Zenklusen et al., 1994b) , and squamous cell carcinoma of the head and neck (Zenklusen et al., 1995b) . One microsatellite marker, D7S522, has been described as the most frequently deleted marker in many dierent tumor types (Achille et al., 1996; Devilee et al., 1997; Zenklusen et al., 1994a) . Chromosomal band 7q31.2 also contains the common fragile site FRA7G, and D7S522 is localized in the middle of the fragile site region (Huang et al., 1998) . Deletions in this region may therefore indicate the presence of a tumor suppressor gene or may simply be the result of the intrinsic instability of a common fragile site region.
Microcell-mediated transfer of human chromosome 7 into a murine squamous cell carcinoma cell line inhibits the tumorigenicity of the cell line (Zenklusen et al., 1994c) . The inserted chromosome delayed the onset of tumors by 2 ± 3-fold and in some cases completely suppressed the tumorigenic capacity of the cell line (Zenklusen et al., 1994c) . Similarly, insertion of an intact human chromosome 7 into an immortalized human ®broblast cell line with 7q31-32 LOH suppressed the immortality of the cells and restored their ability to senesce (Ogata et al., 1993) . These studies provide further evidence for the presence of a TSG on chromosome 7.
Papillary (PTC) and follicular thyroid cancer (FTC) are the most common types of dierentiated thyroid cancer. Both are of epithelial origin and both retain some histologic and functional characteristics of the thyroid epithelium. However, each has distinct histopathology, biological behavior and clinical signi®cance (Hedinger et al., 1989; . The molecular alterations underlying the development of either PTC or FTC are poorly understood. Mutations in the ras proto-oncogene may represent an early event in follicular thyroid tumorigenesis (Lemoine et al., 1989; Suarez et al., 1990) , while ret proto-oncogene rearrangements may be important in PTC (Grieco et al., 1990; Santoro et al., 1992 , Williams et al., 1996 . Unlike many common tumor types, mutations of p53 are seen infrequently in dierentiated thyroid cancer , though they are commonly present in anaplastic and poorly differentiated tumors (Ito et al., 1992) .
Cytogenetic studies have shown frequent chromosome 7 abnormalities in thyroid tumors, including clonal numerical and structural abnormalities (Teyssier et al., 1990; Herrmann and Lalley, 1992) . However, cytogenetic methods detect only gross chromosomal changes. In contrast, LOH analysis with highly polymorphic microsatellite markers is a sensitive molecular method to screen for changes involving allele loss in tumors and will detect microdeletions not visible to cytogenetic analysis. A set of highly polymorphic microsatellite markers on 7q were employed to detect allele loss in dierentiated thyroid cancer. The results indicate that a small region anked by markers D7S480 and D7S490 may harbor a tumor suppressor gene involved in the progression of FA to FTA, while LOH on 7q in PTC involves a dierent site.
Results
We analysed 42 dierentiated thyroid tumors for LOH in a panel of 13 microsatellite markers spanning the region from 7q22 to 7q35 (Table 1) . Eight of these markers map to the region between 7q31.1 and 7q31.2, a region which has been shown to exhibit a high frequency of allele loss in several tumor types (Achille et al., 1996; Devilee et al., 1997; Edelson et al., 1996; Koike et al., 1997; Lin et al., 1996; Oakahashi et al., 1995; Zenklusen et al., 1994a Zenklusen et al., , b, 1995a . Also shown in Table 1 are the overall results showing the number of informative cases, the number of cases with LOH, and %LOH for the entire set of 42 tumors (FTC, PTC, and FA). Representative microsatellite analyses exhibiting LOH are shown in Figure 1 . Overall, 48% (20 of 42) of the tumor specimens showed changes involving at least one marker tested. Tumors exhibiting LOH in at least one of the tested markers are summarized in Figure 2 . FTC showed the most frequent LOH involving 11 of 14 cases (79%) compared to ®ve of the 15 (33%) FA and four of 13 (33%) PTC, a ®nding similar to previously reported studies of LOH on other chromosomes in dierentiated thyroid cancer . The most frequently aected markers in FTC were D7S480 (50%) and D7S490 (55%), which form a smallest common deleted region (SCDR) for FTC ( Figure 2 ). The three adjacent loci (D7S486, D7S522, and D7S487) showed a much lower rate of LOH in the FTC examined while none of the other loci, either proximally or distally, showed LOH in any of the samples examined.
Five of the 15 FA showed LOH at one or more of the loci analysed. Three of 11 informative samples showed LOH of locus D7S486 and one of eight Figure 1 Representative autoradiograms of PCR microsatellite analyses of dierentiated thyroid tumors. Samples were treated as described in Materials and methods. In each case the normal DNA is shown on the left and the tumor DNA is shown on the right. The ®rst sample from FTC11 showed no LOH with D7S480. The second sample from FTC8 showed microsatellite instability with D7S480. The remaining four samples showed LOH. The arrows indicate the alleles that are lost in these four samples informative cases showed LOH of D7S649 which maps to 7q32. However, only two FAs showed LOH of D7S480 and none showed LOH of D7S490, which de®ne the SCDR detected in FTC. Of the 13 PTC, only four showed LOH at any locus and each of these four had LOH at only a single locus, two at D7S522, one at D7S500, and one at D7S495. None of the PTC showed LOH in the FTC SCDR.
There was no correlation between the stage of the FTC and the presence of LOH within the SCDR. Although both of the stage 3 FTC showed LOH in the SCDR, only one of four stage 2 tumors showed LOH in this region, while ®ve of eight of the stage 1 tumors also showed LOH in this region. As previously discussed, only two of the FAs showed LOH within the SCDR. Similarly, life-table analysis indicates no signi®cant correlation between the presence of SCDR deletions and cause-speci®c mortality (data not shown). These results suggest that the SCDR is acquired during the progression from FA to FTC but that the loss is not related to the stage of FTC.
Discussion
The inactivation of tumor suppressor genes is considered to be a critical event in the multi-step genetic process leading to the development of most cancers (Knudson, 1993; Weinberg, 1991) . This inactivation must occur on both alleles and large genomic deletions involving at least one of the alleles of a tumor suppressor gene are seen commonly. The delineation of chromosomal regions which are deleted consistently during carcinogenesis is generally accepted as the ®rst evidence that a speci®c chromosomal region contains a putative tumor suppressor gene. The availability of highly informative microsatellite markers throughout the genome has facilitated these analyses because of the ability to detect microdeletions, not amenable to traditional cytogenetic techniques. In addition, these studies may eventually prove useful as diagnostic markers for dierentiating benign from malignant tumors and possibly for predicting outcomes.
PTC and FTC are the most common thyroid cancers. Both are of epithelial origin, yet each has distinct histopathological features and clinical significance. The underlying mechanisms of thyroid tumorigenesis and tumor progression are not yet known. Follicular neoplasms (FA and FTC) are clonal, arising from a single precursor cell (Hicks et al., 1990; Namba et al., 1990a ). An adenoma to carcinoma sequence is assumed, though direct evidence that FA left untreated can progress to FTC is lacking. In contrast, PTC is commonly multifocal within the gland (McConahey et al., 1986) and evidence for a clonal origin is lacking.
Allelotyping and LOH studies have shown that allele loss in FTC is frequently observed on chromosomes 3p, 3q, 10q, 11p, 11q, 13q, and 22q Herrmann et al., 1991; Matsuo et al., 1991; Zedenius et al., 1996) . One candidate gene is the FHIT gene at 3p14.2 Sozzi et al., 1996) and may be the target of chromosomal 3p loss seen in these tumors. Chromosomal loss in PTC has been observed at 4q, 5p, 7p, 10q, and to a lesser extent 11p. However, the frequency of LOH is substantially lower at almost all loci in PTC than in FTC. The distinct patterns of chromosomal loss in these two tumor types supports the hypothesis that their tumorigenic pathways are distinct.
Mutations of the ras oncogenes have been reported in follicular neoplasms and are regarded as early events in tumor progression as they are found both in FA and in FTC (Hedinger et al., 1989; Namba et al., 1990b; Ogata et al., 1993) . Rearrangements of the ret protooncogene have been reported in a minority of PTC (Grieco et al., 1990; Santoro et al., 1992) in some studies, whereas another study demonstrated RET translocations in 59% of adult onset PTCs (Williams et al., 1996) .
Several reports have shown that LOH at 7q31 is a frequent event in the development of breast, ovarian, and prostate cancer (Devilee et al., 1997; Edelson et al., 1996; Koike et al., 1997; Lin et al., 1996; Oakahashi et al., 1995; Zenklusen et al., 1994a Zenklusen et al., ,b, 1995a . We recently demonstrated that the same region shows frequent loss in sporadic renal cell carcinomas (Shridhar et al., 1997) . The SCDR for these cancers occurs within a region that also contains FRA7G, an aphidicolininducible fragile site. Using a somatic cell hybrid whose only human component is an intact chromosome 7 and FISH analysis, our laboratory has identi®ed several overlapping YAC clones which span FRA7G (Huang et al., 1998) . Interestingly, these clones map precisely to the common region of LOH in the various cancers. The locus D7S522 and the met oncogene are both contained within the region of overlap between these three YAC clones. However, chromosomal loss within a fragile site region could be due to intrinsic instability in the fragile site region during cancer progression rather than to the presence of a putative TSG.
We undertook the current study to see if thyroid cancers showed similar LOH in the FRA7G region. Two of six informative PTCs did show LOH of D7S522, but only one of nine informative FTCs showed LOH for this marker; only a single FA was informative for this marker and no loss was detected. However, we did detect frequent loss in the FTC samples with more telomeric markers. Five of 10 and ®ve of 11 informative FTCs showed loss for D7S480 and D7S490 respectively, while none of the PTC and only one of the FA showed LOH at either locus. These two markers, separated by only 2 cM, de®ne a narrow SCDR which appears to be speci®c for FTC and distinct from the FRA7G fragile site, suggesting that the chromosomal loss observed in the FTCs is not the result of intrinsic instability of the SCDR region. This SCDR may therefore encompass a TSG involved in the progression from FA to FTC. We are currently working to better de®ne this region and to search for candidate TSGs involved in this progression.
In addition to providing evidence on the molecular pathogenesis of follicular neoplasms, markers of malignancy might prove useful in distinguishing the benign FA from the malignant FTC, which currently is possible only after excision. Umbricht et al., (1997) recently reported that telomerase activity might be a useful marker to dierentiate FA from FTC. Our results with LOH in the D7S480 to D7S490 region may provide a further molecular marker of this distinction, though prospective studies in larger numbers of patients are clearly indicated.
Materials and methods

Specimen collection and DNA extraction
These studies were approved by the Mayo Clinic Institutional Review Board, and all patients gave informed consent prior to tissue or blood sampling. Tumor and matching peripheral blood specimens were obtained from 42 patients undergoing surgery for either primary (n=33) or recurrent (n=9) follicular cell-derived thyroid tumors between January 1987 and June 1991. The tumors included 14 FTC, 15 follicular adenomas (FA), and 13 papillary thyroid carcinomas (PTC). Clinical and pathologic information is summarized in Table 2 .
Tumor specimens were snap frozen in liquid nitrogen at the time of surgery and stored at 7708C until DNA extraction. DNA from the matching normal blood samples was extracted immediately and stored at 48C. All tumor samples were reviewed histologically by a single pathologist (JRG) in order to con®rm the diagnosis, and frozen sections of the cryo-preserved tumors were examined to establish that tumor samples contained a minimum neoplastic cell content of 70%. For DNA extraction, tumor samples were homogenized. Blood and tumor DNA was extracted and puri®ed using standard procedures based on ionic detergent lysis and proteinase K digestion, followed by repeated phenol-chloroform extraction, precipitation in absolute ethanol, and two consecutive 70% ethanol washes. Extracted DNA samples were redissolved in 10 mM Tris-HCl, 1 mM EDTA (pH 7.5) and stored at 48C until use.
PCR and microsatellite analysis
Thirteen pairs of primers for microsatellite markers on chromosome 7q were used (Research Genetics, Huntsville, AL). The analysed loci and their map positions are shown in Table 2 . The forward primer of each primer pair was end-labeled with T4 polynucleotide kinase and g-32 P-ATP. The reaction mix contained: 50 ± 100 ng of genomic DNA, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 200 mM of each dNTP, 200 mM of each primer, and 0.5 units of Taq polymerase (Promega) in a 15 ml reaction volume. The reactions were ampli®ed in a Perkin Elmer 480 thermocycler with the following conditions: 958C for 3 min, then 35 cycles of 948C for 30 s, 55 ± 568C for 30 s and 728C for 30 s; after 35 cycles there was a ®nal extension step at 728C for 5 min.
The PCR products were heat-denatured and separated on 7% polyacrylamide sequencing gels containing 8 M urea. The gels were dried and autoradiographed for 16 ± 24 h and then scored for LOH; multiple exposures were used before scoring for LOH. Allelic imbalance indicative of LOH was scored when there was a loss of intensity of one allele in a tumor sample with respect to the matched allele from normal tissue. The evaluation of the intensity of the signal between dierent alleles was determined by two independent viewers (JSZ and MN) who were blinded to the histological diagnosis. 
